At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 148 enrolled
Drug / intervention
Bortezomibdrug
Likely dose
Bortezomib 1.6mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
In Brief
A Phase 3 clinical trial evaluating Bortezomib for Multiple Myeloma and Auto Stem Cell Transplant. Completed, enrolled 148 participants across 1 site.
Detailed Summary
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Auto Stem Cell Transplant
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedNov 2010
Primary CompletionJul 2023
TodayJul 2026
First PostedNov 16, 2010
Enrollment StartApr 8, 2010
Primary CompletionJul 15, 2023
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 15.6 years ago
Interventions
Bortezomibdrug
Bortezomib 1.6mg/m2 on day -4 and day -1